Literature DB >> 10638581

Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.

I E Koutroubakis1, A Sfiridaki, I A Mouzas, A Maladaki, A Kapsoritakis, M Roussomoustakaki, E A Kouroumalis, O N Manousos.   

Abstract

OBJECTIVE: Patients with inflammatory bowel disease (IBD) frequently suffer from thromboembolic events. A recently identified mechanism for thrombophilia, the poor anticoagulant response to activated protein C, has been suggested as one of the leading risk factors for thrombosis. The aim of this study was to evaluate the frequency of thrombophilic abnormalities, including activated protein C-resistance (APCR), in Greek patients with ulcerative colitis (UC) and Crohn's disease (CD).
METHODS: Forty-eight patients with UC, 36 with CD, and 61 matched healthy controls (HC) were studied. Cases with presence of lupus anticoagulant, use of anticoagulants or heparin, and pregnancy were excluded. Disease activity in CD was evaluated by use of the Crohns Disease Activity Index (CDAI) score and in UC by the Truelove-Witts grading system. Plasma levels of protein C, free protein S, antithrombin III (AT-III), activated protein C resistance (APCR), and fibrinogen were determined in IBD patients, as well as in HC. All the cases and controls with abnormal APCR were further studied by genetic testing for the factor V Leiden mutation.
RESULTS: Mean fibrinogen levels in UC and CD patients were significantly elevated (p<0.0001), compared with HC. The mean values of free protein S, as well as mean APCR, were significantly lower in UC and CD patients than in the HC (p<0.0001). Seven (five UC and two CD) of 84 IBD patients (8.3%) and three of the HC (4.9%) had the factor V Leiden mutation. No significant difference was observed for the other thrombophilic parameters. Fibrinogen levels and profound free protein S deficiency were found related to disease activity.
CONCLUSIONS: Thrombophilic defects are common in Greek patients with IBD and they could interfere either in the disease manifestation or in the thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638581     DOI: 10.1111/j.1572-0241.2000.01683.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

1.  Hyperhomocysteinemia in Greek patients with inflammatory bowel disease.

Authors:  I E Koutroubakis; E Dilaveraki; I G Vlachonikolis; E Vardas; G Vrentzos; E Ganotakis; I A Mouzas; A Gravanis; D Emmanouel; E A Kouroumalis
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease?

Authors:  Emma Attvall; Attila Frigyesi; Berit Sternby
Journal:  Int J Colorectal Dis       Date:  2006-01-13       Impact factor: 2.571

Review 3.  TAM receptor signaling in immune homeostasis.

Authors:  Carla V Rothlin; Eugenio A Carrera-Silva; Lidia Bosurgi; Sourav Ghosh
Journal:  Annu Rev Immunol       Date:  2015-01-14       Impact factor: 28.527

Review 4.  Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.

Authors:  Carla V Rothlin; Jonathan A Leighton; Sourav Ghosh
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

Review 5.  Coagulopathies and inflammatory diseases: '…glimpse of a Snark'.

Authors:  Silvina Del Carmen; Sophie M Hapak; Sourav Ghosh; Carla V Rothlin
Journal:  Curr Opin Immunol       Date:  2018-09-27       Impact factor: 7.486

6.  Hyperhomocysteinemia in ulcerative colitis is related to folate levels.

Authors:  Petros Zezos; Georgia Papaioannou; Nikolaos Nikolaidis; Themistoclis Vasiliadis; Olga Giouleme; Nikolaos Evgenidis
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

Review 7.  Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Jie Liang; Shengjun Wu; Bin Feng; Shaoni Lei; Guanhong Luo; Jingbo Wang; Kai Li; Xiaohua Li; Huahong Xie; Dexin Zhang; Xin Wang; Kaichun Wu; Danmin Miao; Daiming Fan
Journal:  J Gastroenterol       Date:  2011-07-30       Impact factor: 7.527

8.  Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia.

Authors:  Bas Oldenburg; Bas A C Van Tuyl; René van der Griend; Rob Fijnheer; Gerard P van Berge Henegouwen
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 9.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 10.  Thrombosis and inflammatory bowel disease-the role of genetic risk factors.

Authors:  Georgia Tsiolakidou; Ioannis-E Koutroubakis
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.